Table 1.
HPV identification in cervical neoplasia and subsequent breast cancer.
| Patient | Age | Diagnosis | HPV E7 | HPV |
|---|---|---|---|---|
| Immunohistochemistry | PCR consolidated | |||
| 1. Cervix | 46 | CIN1 | HPV 16/18 | |
| Breast | 48 | IDC | Neg | HPV 18 |
| 2. Cervix | 60 | Normal | Neg | |
| Breast | 66 | IDC Gr3 | Neg | HPV 18 |
| 3. Cervix | 62 | CIN1 | HPV 18 | |
| Breast | 73 | DCIS | 2+ | HPV 18 |
| 4. Cervix | 53 | CIN3 | HPV 18 | |
| Breast | 62 | IDC Gr2 | ||
| 5. Cervix | 44 | CIN2 | HPV 18 | |
| Breast | 45 | IDC Gr2 | Neg | HPV 18 |
| 6. Cervix | 42 | HPV koilos | Neg | |
| Breast | 47 | IDC Gr2 | 3+ | HPV 18 |
| 7. Cervix | 39 | CIN3 | ||
| Breast | 45 | ILC Gr2 | 3+ | Neg |
| 8. Cervix | 40 | CIN3 | HPV 18 | |
| Breast | 45 | IDC Gr3 | 3+ | HPV 18 |
| 9. Cervix | 33 | CIN2 | HPV 18 | |
| Breast | 39 | IDC Gr2 | 3+ | HPV 18 |
| 10. Cervix | 44 | HPV koilos | HPV 18 | |
| Breast | 44 | DCIS | Neg | HPV 18 |
| 11. Cervix | 57 | HPV koilos | HPV 18 | |
| Breast | 68 | IDC Gr3 | Neg | HPV 18 |
| 12. Cervix | 43 | CIN3 | HPV 16/18 | |
| Breast | 45 | IDC Gr2 | HPV 18 | |
| 13. Cervix | 29 | CIN 2 | HPV 16 | |
| Breast | 32 | IDC | 3+ | HPV 18 |
| 14. Cervix | 46 | HPV koilos | HPV 18 | |
| Breast | 47 | IDC Gr2 | 1+ | HPV 18 |
| 15. Cervix | 41 | CIN1 | ||
| Breast | 46 | IDC Gr1 | 2+ | HPV 18 |
| 16. Cervix | 41 | CIN2 | HPV 16/18/58 | |
| Breast | 50 | IDC Gr2 | 1+ | HPV 58 |
| 17. Cervix | 33 | CIN3 | HPV 18 | |
| Breast | 34 | IDC Gr3 | Neg | HPV 18 |
| 18. Cervix | 29 | HPV koilos | Neg | |
| Breast | 38 | I Muc C Gr2 | HPV 16/18 | |
| 19. Cervix | 55 | CIN1 | ||
| Breast | 62 | IDC Gr1 | 2+ | HPV 18 |
| 20. Cervix | 57 | CIN1 | HPV 18 | |
| Breast | 67 | IDC Gr1 | 1+ | HPV 16/18 |
| 21. Cervix | 36 | CIN1 | Neg | |
| Breast | 40 | IDC Gr1 | 1+ | Neg |
| 22. Cervix | 54 | CIN1 | HPV | |
| Breast | 64 | IDC Gr2 | 2+ | HPV 18 |
| 23. Cervix | 39 | CIN2 | HPV | |
| Breast | 47 | ILC Gr2 | 1+ | Neg |
| 24. Cervix | 46 | CIN3 | HPV 16/18 | |
| Breast | 52 | IDC Gr1 | Neg | HPV 18 |
| 25. Cervix | 53 | CIN1 | HPV 18 | |
| Breast | 61 | IDC Gr2/DCIS | 3+ | Neg |
| 26. Cervix | 44 | CIN3 | Neg | |
| Breast | 45 | IDC Gr3 | Neg | |
| 27. Cervix | 44 | Normal | HPV 18 | |
| Breast | 48 | DCIS | 3+ | HPV 18 |
| 28. Cervix | 50 | HPV koilos | HPV 18 | |
| Breast | 61 | IDC Gr1 | Neg | HPV 16/18 |
PCR and immunohistochemistry results using different techniques for patients 1–28.
CIN, cervical intraepithelial neoplasia; DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; Gr, grade.
Genomic extractions were tested for PCR availability before proceeding to screen for HPV. Not all extractions were successful. A different extraction was used for the real-time PCR. Not all specimens were suitable for in situ PCR.